Evidence map›Paper›PMID 41502900›Full record

ArticleTranslational pediatrics2025

Challenge of

Yue Hou, Wenqin Xie, Jinyue Duan, Xuankun Li, Zhu Wu

Abstract readCase Reports
In one paragraph

Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yue HouDepartment of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0009-0004-0693-0871
Wenqin XieDepartment of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jinyue DuanDepartment of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xuankun LiDepartment of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhu WuDepartment of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Case Description: A 4-year-old boy with acute lymphoblastic leukemia developed severe immunosuppression after reinduction cyclophosphamide, cytarabine (Ara-C), mercaptopurine (CAM) chemotherapy according to the SCCCG-ALL-2023 protocol. The patient initially presented with recurrent fever, septic shock, and progressive respiratory distress. Despite an aggressive empirical antibiotic regimen including meropenem, imipenem, piperacillin-tazobactam, linezolid, and levofloxacin, his condition continued to worsen. Blood cultures and metagenomic next-generation sequencing (mNGS) subsequently confirmed Conclusions: This case demonstrates that CAZ-AVI may offer effective antimicrobial control for

Indexed as

case reportceftazidime-avibactam (CAZ-AVI)Cupriavidus gilardiiimmunodeficiencypediatric

Identifiers

PMID41502900
PMCPMC12771200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.